Abstract
Human papilloma virus (HPV) is the primary etiological agent responsible for cervical cancer in women. Although in total 16 high-risk HPV strains have been identified so far. Currently available commercial vaccines are designed by targeting mainly HPV16 and HPV18 viral strains as these are the most common strains associated with cervical cancer. Because of the high level of antigenic specificity of HPV capsid antigens, the currently available vaccines are not suitable to provide cross-protection from all other high-risk HPV strains. Due to increasing reports of cervical cancer cases from other HPV high-risk strains other than HPV16 and 18, it is crucial to design vaccine that generate reasonable CD8+ T-cell responses for possibly all the high-risk strains. With this aim, we have developed a computational workflow to identify conserved cross-clade CD8+ T-cell HPV vaccine candidates by considering E1, E2, E6 and E7 proteins from all the high-risk HPV strains. We have identified a set of 14 immunogenic conserved peptide fragments that are supposed to provide protection against infection from any of the high-risk HPV strains across globe.Electronic supplementary materialThe online version of this article (doi:10.1007/s13205-015-0352-z) contains supplementary material, which is available to authorized users.
Highlights
Cervical cancer is the second most common malignant cancer in terms of incidence and mortality rates in women worldwide after breast cancer (Pisani et al 1993; Collins et al 2006; Jemal et al 2011; Senapathy et al 2011; Torre et al 2015)
We identified conserved consensus immunogenic CD8? T-cell epitopes from the proteome of all high-risk Human papilloma virus (HPV) strains and proposed a peptide pool with the ability to show immunogenic responses against all the known high-risk HPV strains
Since E1 and E2 are expressed in higher levels than E6 and E7 early in the progress of an HPV infection, it may be assumed that these proteins may considered as good targets for vaccine
Summary
Cervical cancer is the second most common malignant cancer in terms of incidence and mortality rates in women worldwide after breast cancer (Pisani et al 1993; Collins et al 2006; Jemal et al 2011; Senapathy et al 2011; Torre et al 2015). Human papilloma virus (HPV) is considered as the major etiological agent for cervical cancer which is responsible for over 265,700 total women deaths per year with around 527,600 new cases every year (Torre et al 2015). Every woman who dies due to cervical cancer loses about 26 years of life which is considerably greater than the average years of life lost to 39 Page 2 of 10
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
